• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer

byDavid XiangandHarsh Shah
March 17, 2022
in Endocrinology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer.  

2. Ribociclib plus Letrozole provided a median overall survival of more than 12 months longer than Ribociclib alone.

Evidence Rating Level: 1 (Excellent)

Study Rundown: HER-2 negative disease is the most common subtype of metastatic breast cancer and is incurable. Pre-clinically, ribociclib had been shown to inhibit CDK4, a kinase that plays a key function in promoting cancer growth, and had been shown to have high drug concentrations at clinically relevant doses. However, there is a gap in knowledge as to evaluating overall survival among patients receiving first-line therapy. This study found that first-line treatment of ribociclib plus letrozole, an aromatase inhibitor, provided a significant and clinically meaningful difference in overall survival of 12.5 months compared to letrozole alone in postmenopausal patients with advanced HR-positive, HER2-negative breast cancer, with a relative reduction in risk of death by 24%. This study was limited by other trials investigating CD4/6 inhibitors as first-line therapy still undergoing reporting final overall survival and thus limit the applicability of this singular trial’s results. Nevertheless, these study’s findings are significant, as they demonstrate that ribociclib plus letrozole as first-line therapy for advanced breast cancer can provide significant overall survival benefit and decreased risk of death in these patients.

Click to read the study in NEJM

Relevant Reading: Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

In-Depth [randomized control study]: This randomized control study followed patients who were assigned either ribociclib plus letrozole for treatment or placebo plus letrozole. Patients who were postmenopausal with locally confirmed, HR-positive, HER-2 negative recurrent or metastatic breast cancer who had not received previous systemic therapy were eligible for the study. Patients who had received previous treatment with a CDK4/6 inhibitor or any previous systemic endocrine therapy or chemotherapy were not eligible. The primary outcome was investigator-assessed progression-free survival with overall survival as the key secondary endpoint. Outcomes in the primary analysis were conducted with the Kaplan-Meier method and stratified Cox proportional-hazards model. Based on the analysis, with a median follow-up of 6.6 years, 54.2% of patients in the ribociclib group had died and 65.6% of patients in the placebo group had died. ribociclib plus Letrozole showed significant overall survival benefit as compared to placebo with letrozole, as median overall survival was 63.9 months (95% confidence interval [CI], 52.4 to 71.0) in the ribociclib group compared to 51.4 months (95% CI, 47.2 to 59.7) in the placebo group. The Kaplan-Meier estimate of overall survival at 5 years was 52.3% (95% CI, 46.5 to 57.7) in the ribociclib group compared to 43.9% (95% CI, 38.3 to 49.4) in the placebo group. Overall, this study demonstrated that ribociclib plus letrozole as compared to placebo plus letrozole provided an overall survival benefit of 12.5 months in patients with advanced HER-2 negative breast cancer.

RELATED REPORTS

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Several factors influence health programs conducted in the African American Church

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced breast cancerBreast CancerHER-2 negativeHR-positiveletrozolemetastatic breast cancerpostmenopausalrecurrent breast cancerribociclib
Previous Post

Wellness Check: Addictions

Next Post

Breast cancer overdiagnosis rates not as high as estimated previously

RelatedReports

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 3, 2022
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Oncology

Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation

April 26, 2022
Next Post
Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Breast cancer overdiagnosis rates not as high as estimated previously

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Overdoses in youth with benzodiazepine and stimulant prescriptions

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.